-
Clovis Oncology's 45% Pre-Market Surge, Explained
Monday, June 19, 2017 - 7:21am | 386Read More...Shares of Clovis Oncology Inc (NASDAQ: CLVS), a biopharmaceutical company that develops an ovarian cancer drug called Rubraca (rucaparib), surged higher by 45 percent early Monday morning after the company released encouraging late-stage data from an ongoing trial called ARIEL3. Clovis' ARIEL3 is a...
-
Clovis Oncology Issues Update On Rociletinib, Will Meet With FDA On April 12
Friday, February 12, 2016 - 11:09am | 189Read More...Clovis Oncology Inc (NASDAQ: CLVS) announced on Friday that the U.S. Food and Drug Administration has scheduled a date of April 12, 2016 to discuss a New Drug Application for its rociletinib therapy. Rociletinib is an investigational therapy for the treatment of patients with mutant epidermal...
-
Clovis Oncology Plunges 70% In One Morning: What Happened?
Monday, November 16, 2015 - 11:00am | 507Read More...Shares of Clovis Oncology Inc (NASDAQ: CLVS) plunged more than 70 percent on Monday, establishing a new multi-year low of $26.05. Shares of Clovis were initially halted early Monday morning as the company reported that the FDA submitted a request for additional information on the company...
